Blackstone’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
Other funds holding ELVN
Blackstone's ELVN Position: Q2 2026 in Review
Blackstone opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 215,744 shares worth $10.9M. The stake represents 0.03% of the portfolio and ranks #96 among its holdings. This is a return to the name: Blackstone previously reported a position in ELVN as recently as Q4 2025.
Blackstone first reported a position in ELVN in Q1 2024 and has held it in 9 quarters since. The position peaked at $27M in Q3 2025. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.
- Blackstone held 215,744 shares of Enliven Therapeutics worth $10.9M as of Q2 2026.
- Enliven Therapeutics was a new Blackstone position in Q2 2026.
- Enliven Therapeutics made up 0.03% of Blackstone's portfolio in Q2 2026, its #96 holding.
- Blackstone first reported a position in Enliven Therapeutics in Q1 2024 and has held it in 9 quarters since.
- Blackstone's Enliven Therapeutics position peaked at $27M in Q3 2025.
- 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.
Based on Blackstone's 13F filing for Q2 2026, filed 14 Aug 2026.